. Author manuscript; available in PMC: 2023 Jul 27.

Published in final edited form as: Brachytherapy. 2022 Jun 17;21(5):599–604. doi: 10.1016/j.brachy.2022.04.006

Table 2.

Post-implant dosimetry for LDR cohort ( n = 40) and intraoperative dosimetry for HDR cohort ( n = 59)

	LDR cohort	HDR cohort
	Median (IQR)	Median (IQR)
Prostate V150 (%)	65.0 (61.25–71.0)	41.3 (38.2–45.3)
Prostate V100 (%)	93.5 (91–96.0)	97.0 (95.6–97.8)
Prostate D90 (%)	106.53 (102.0–117.75	110.9 (108.3–112.7)
Urethra D05 (%)	132.0 (120.25–140.95)	0.0 (0.0–0.0)
Urethra D20 (%)	118.50(110–129.0)	115.2 (112.0–118.7)
Rectum V100 (cc)	0 (0–0.006)	112.6 (108.6–116.1)

V150 = volume receiving 150% of prescription dose; V100 = volume receiving 100% of prescription dose; D90 = dose received by 90% of volume; D05 = dose received by 5% of volume;